



28th April 2026

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544250

The Secretary
National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICONR

Sub.: Outcome of Board Meeting held on Tuesday, 28th April 2026

Dear Sir/Madam,

We refer to our letter dated 23rd April 2026 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Tuesday, 28th April 2026, *inter-alia* considered and approved the Unaudited Financial Results for the quarter ended 31st March 2026.

Further, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we enclose herewith a copy of the Unaudited Financial Results for the quarter ended 31st March 2026, as approved at the aforesaid meeting, along with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI Listing Regulations. The aforesaid financial results will also be available on the Company's website at <https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results>

The meeting of Board of Directors commenced at 1:00 p.m. and concluded at 3:40 p.m.

Kindly take the above information on record.

Thanking you.

Yours faithfully,
For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: L21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026

Particulars	(₹ in Million)			
	Quarter ended 31.03.2026 (Unaudited)	Quarter ended 31.12.2025 (Unaudited) Refer Note 9	Quarter ended 31.03.2025 (Unaudited)	Year ended 31.12.2025 (Audited)
1. Revenue from Operations (Refer note 8)	2,292	2,510	1,726	8,784
2. Other Income	56	46	52	184
3. Total Income (1+2)	2,348	2,556	1,778	8,968
4. Expenses				
(a) Cost of Materials Consumed	402	499	189	1,607
(b) Purchases of stock in trade	181	61	335	702
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	(21)	123	(136)	(8)
(d) Employee benefits expense (Refer note 4)	331	355	296	1,288
(e) Finance costs	5	5	4	20
(f) Depreciation and amortisation expense	32	34	20	117
(g) Other expenses	511	574	402	2,105
Total Expenses	1,441	1,651	1,110	5,831
5. Profit before exceptional items and tax (3-4)	907	905	668	3,137
6. Exceptional items (Refer note 5)	-	-	-	66
7. Profit before tax (5+6)	907	905	668	3,203
8. Tax expense				
Current Tax	241	241	170	820
Deferred Tax	(12)	(1)	(2)	(18)
9. Profit for the period / year (7-8)	678	665	500	2,401
10. Other comprehensive income (OCI)				
Items that will not be reclassified to the statement of profit and loss				
- Remeasurements of post-employment benefit obligations	-	(19)	-	(19)
- Income Tax impact relating to these items	-	5	-	5
11. Total comprehensive income for the period/year (9+10)	678	651	500	2,387
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230
13. Other equity	-	-	-	3,610
14. Basic and diluted earnings per share (not annualised) (in ₹)	29.44	28.87	21.69	104.27

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with their LODR Regulations review report dated April 28, 2026.

Damarla Sai Venkata Ramana

Digitally signed by Damarla Sai Venkata Ramana
DN: cn=H, o=Personal, 1.6=0221,
pseudoym=13317923944578480x29PPD25891 SV,
2.5.4.20=f99901185106251097026015188fabc99b81609de741b67
902946c02a105c.ppt@icodes=421301, st=Maharashtra,
serialNumber=608531 0d41 d0b64abb985e0dc-iced3e8d17f71e8
ccc85c0d6194469b9127a, cn=Damarla Sai Venkata Ramana
Date: 2026.04.28 16:08:51 +05'30'

Himanshu Bakshi
Digitally signed by Himanshu Bakshi
Date: 2026.04.28 16:02:01 +05'30'

Notes:

1. These unaudited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards (“Ind AS”), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The statutory auditors have issued a limited review report with an unmodified conclusion on the above unaudited financial results for the quarter ended March 31, 2026. The unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 have been reviewed by the Audit Committee in their meeting held on April 28, 2026 and approved by the Board of Directors of the Company at its meeting held on April 28, 2026
3. In 2024, the Company had voluntarily decided to recall Depura Kids, Allegra Suspension and Combiflam Suspension from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the Company has successfully relaunched, Combiflam Suspension during the quarter ended June 2025 and Allegra Suspension and Depura Kids in quarter ended September 2025. Consequently, there were no sales of Depura Kids, Allegra Suspension and Combiflam Suspension in quarter ended March 31, 2025 and hence to that effect, the results are not comparable with the corresponding quarter of the previous year as the product recall and subsequent relaunches had an impact on the domestic business.
4. The Government of India notified four New Labour Codes effective November 21, 2025 replacing the existing 29 Labour laws. The Ministry of Labour & Employment has also issued draft Central Rules and FAQs to help assess the financial impact of these changes. The Company has ascertained its estimated obligations under the New Labour Codes based on actuarial valuation, best estimates and consistent with guidance provided by the Institute of Chartered Accountants of India.

The Company has recognised an incremental financial impact of ₹ 24 million as past service cost resulting in an increase in gratuity liability and compensated absences, arising due to change in the definition of wages, under Employee Benefits Expense in the quarter and year ended December 31, 2025. The Company will continue to monitor the finalization of the relevant Central and State Rules and will evaluate impact, if any, on the measurement of employee benefits and will provide appropriate accounting treatment in the period in which such rules or related clarifications are notified.

5. Exceptional items for year ended December 31, 2025 pertain to a reversal of ₹66 million related to demerger provisions made in the previous year.
6. The Company has a single business segment namely ‘Pharmaceutical Business’. Therefore, disclosure relating to segments under Ind AS 108 is not applicable and accordingly not made
7. The Company does not have any subsidiary, associates or joint ventures as on March 31, 2026.
8. Revenue from operations includes sales of products and service income. Sales of products as under

₹ in Million

Particulars	Quarter ended (Unaudited)			Year ended (Audited)
	31.03.2026	31.12.2025	31.03.2025	31.12.2025
Sales of Product	2,063	2,330	1,586	8,045

For the quarter ended March 31, 2026, Domestic sales grew by 15.5% aided by relaunch and Export sales grew by 144.4% on lower base as compared to quarter ended March 31, 2025

9. The figures for the quarter ended December 31, 2025 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2025 and the unaudited published year-to-date figures up to September 30, 2025 which were subject to a limited review, being the date of the end of the third quarter of the said financial year.

Damarla
Sai
Venkata
Ramana

Digitally signed by Damarla Sai
Venkata Ramana
DN: c=IN, ou=Personal, title=S21,
serialNumber=1333179239457840x,
2.5.4.20=956991859d6251d9702d601
299f2e5d9137,
51b8fabcf99d61b99d6741b6740d93
4acfd2a1063, postalCode=421301,
st=Maharashtra,
serialNumber=6083106d1d0b64abb
d98566db4cc93b8d17771e8cc65cd
dd19446b2b121a, cn=Damarla Sai
Venkata Ramana
Date: 2026.04.28 16:09:32 +05'30'

Place: Mumbai
April 28, 2026

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu
u Bakshi

Digitally signed
by Himanshu
Bakshi
Date: 2026.04.28
16:02:45 +05'30'

Himanshu Bakshi
Managing Director
DIN: 08188412